Green Cross Medical Science Corp

Green Cross Medical Science Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.39, below the industry median of 0.55, indicating a lower reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.15, suggesting it has sufficient short-term assets to cover its short-term liabilities but with limited buffer. Free cash flow of KRW 2.67 billion indicates the company generates positive cash from operations after capital expenditures, supporting operational flexibility. Profitability metrics show a return on equity (ROE) of 8.26% and a return on assets (ROA) of 4.05%, both below the industry median of 10.5% and 5.2%, respectively. This suggests the company is underperforming its peers in terms of capital efficiency and asset utilization. Operating income of KRW 2.74 billion and net income of KRW 3.67 billion reflect a healthy margin, but the gross profit margin of 14.0% is also below the industry median of 18.5%. The company's revenue is distributed across four segments, with the Diagnostic Reagents Business and Hemodialysis Fluid Business likely representing the largest portions. However, the input data does not provide specific revenue shares for each segment, so the exact concentration is unclear. The geographic exposure is primarily to South Korea, with no significant international revenue disclosed in the financial snapshot. Looking ahead, the company's growth trajectory is expected to be modest, with no specific numeric deltas provided in the outlook. Historical revenue of KRW 108.41 billion indicates a stable base, but the absence of forward-looking guidance suggests limited visibility into future performance. The risk assessment highlights a key flag of negative net cash after subtracting total debt, which could constrain the company's ability to invest in growth opportunities. The company's dilution risk is assessed as low, with no near-term pressure expected. The absence of dilution sources in the input data supports this assessment, as there are no recent issuances or shelf registrations disclosed. Recent events, such as filings or transcripts, are not provided in the input data, so no specific developments can be cited.